BR112015013260A2 - uso de inibidores de telomerase para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas - Google Patents

uso de inibidores de telomerase para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas

Info

Publication number
BR112015013260A2
BR112015013260A2 BR112015013260-0A BR112015013260A BR112015013260A2 BR 112015013260 A2 BR112015013260 A2 BR 112015013260A2 BR 112015013260 A BR112015013260 A BR 112015013260A BR 112015013260 A2 BR112015013260 A2 BR 112015013260A2
Authority
BR
Brazil
Prior art keywords
myeloproliferative
telomerase inhibitors
treatment
myeloproliferative disorders
neoplasms
Prior art date
Application number
BR112015013260-0A
Other languages
English (en)
Inventor
J. Stuart Monic
Kelsey Stephen
Original Assignee
Geron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed by Geron Corporation filed Critical Geron Corporation
Publication of BR112015013260A2 publication Critical patent/BR112015013260A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

resumo uso de inibidores de telomerase para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas são fornecidos neste documento métodos para reduzir a proliferação de células progenitoras neoplásicas e para aliviar os sintomas associados em indivíduos diagnosticados ou com suspeita de ter distúrbios mieloproliferativos, tais como trombocitemia essencial (et). também são fornecidos neste documento métodos para usar inibidores de telomerase para manter as contagens de plaquetas sanguíneas em intervalos relativamente normais no sangue de indivíduos diagnosticados ou com supeita de ter distúrbios mieloproliferativos, tais como et.
BR112015013260-0A 2012-12-07 2013-11-15 uso de inibidores de telomerase para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas BR112015013260A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US61/734,941 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US13/841,711 2013-03-15
US61/799,069 2013-03-15
US201361900347P 2013-11-05 2013-11-05
US61/900,347 2013-11-05
PCT/US2013/070437 WO2014088785A1 (en) 2012-12-07 2013-11-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Publications (1)

Publication Number Publication Date
BR112015013260A2 true BR112015013260A2 (pt) 2018-02-06

Family

ID=50883867

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015013260-0A BR112015013260A2 (pt) 2012-12-07 2013-11-15 uso de inibidores de telomerase para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas

Country Status (33)

Country Link
EP (3) EP2928477B1 (pt)
JP (5) JP6433911B2 (pt)
KR (2) KR20230028590A (pt)
CN (2) CN104936602B (pt)
AP (1) AP2015008504A0 (pt)
AU (3) AU2013356533B2 (pt)
BR (1) BR112015013260A2 (pt)
CA (2) CA3188494A1 (pt)
CL (2) CL2015001530A1 (pt)
CY (2) CY1122169T1 (pt)
DK (3) DK3456333T3 (pt)
EA (1) EA032973B1 (pt)
ES (2) ES2789176T3 (pt)
HK (2) HK1210940A1 (pt)
HR (2) HRP20191784T1 (pt)
HU (2) HUE049858T2 (pt)
IL (2) IL239266B (pt)
LT (2) LT2928477T (pt)
MA (2) MA38193B1 (pt)
ME (1) ME03538B (pt)
MX (3) MX2015007169A (pt)
MY (1) MY180634A (pt)
NZ (1) NZ708920A (pt)
PH (1) PH12015501282A1 (pt)
PL (2) PL3456333T3 (pt)
PT (2) PT3456333T (pt)
RS (2) RS60401B1 (pt)
SG (3) SG10202103341SA (pt)
SI (2) SI3456333T1 (pt)
TN (1) TN2015000249A1 (pt)
UA (2) UA117116C2 (pt)
WO (1) WO2014088785A1 (pt)
ZA (2) ZA201504124B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054463T2 (hu) 2004-07-02 2021-09-28 Geron Corp Védett 3'-amino 5'-foszforamidit nukleozid monomerek szintézise
AU2014346840B2 (en) * 2013-11-06 2020-02-06 Mayo Foundation For Medical Education And Research Methods and materials for treating hematological malignancies
SI3286203T1 (sl) 2015-04-23 2020-10-30 Geron Corporation Metode priprave polinukleotida, z uporabo sestavkov multivalentne kationske soli
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
WO2019023667A1 (en) 2017-07-28 2019-01-31 Janssen Biotech, Inc. METHODS OF TREATING MYELODYSPLASTIC SYNDROME
CA3098606A1 (en) * 2018-04-30 2019-11-07 Kartos Therapeutics, Inc. Methods of treating cancer
CN115666588A (zh) * 2019-11-04 2023-01-31 美国杰龙生物医药公司 Janus激酶抑制剂和端粒酶抑制剂用于治疗骨髓增殖性肿瘤的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
EP0951568A1 (en) 1996-12-20 1999-10-27 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
CA2515000A1 (en) * 2003-01-31 2004-08-19 Jessie L.-S. Au Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
KR101298493B1 (ko) 2003-09-09 2013-08-21 제론 코포레이션 텔로머라제 억제를 위한 변형 올리고뉴클레오티드
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
HUE054463T2 (hu) 2004-07-02 2021-09-28 Geron Corp Védett 3'-amino 5'-foszforamidit nukleozid monomerek szintézise
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
ATE553198T1 (de) 2005-04-15 2012-04-15 Geron Corp Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
CA2892907A1 (en) 2014-06-12
AU2020267142A1 (en) 2020-12-03
LT3456333T (lt) 2020-06-25
MA45504B1 (fr) 2021-10-29
UA126015C2 (uk) 2022-08-03
CN104936602A (zh) 2015-09-23
CA3188494A1 (en) 2014-06-12
AU2018282364A1 (en) 2019-05-23
JP2022050537A (ja) 2022-03-30
ES2744790T3 (es) 2020-02-26
RS60401B1 (sr) 2020-07-31
LT2928477T (lt) 2019-10-10
WO2014088785A1 (en) 2014-06-12
MY180634A (en) 2020-12-03
JP7288098B2 (ja) 2023-06-06
HRP20191784T1 (hr) 2019-12-27
EP3456333B1 (en) 2020-04-01
IL280144A (en) 2021-03-01
ZA201504124B (en) 2017-05-31
ES2789176T3 (es) 2020-10-26
PL2928477T3 (pl) 2020-03-31
UA117116C2 (uk) 2018-06-25
EP3456333B8 (en) 2020-05-13
EA201590878A1 (ru) 2016-04-29
SI3456333T1 (sl) 2020-10-30
CY1123206T1 (el) 2021-10-29
DK3456333T3 (da) 2020-05-18
PT2928477T (pt) 2019-10-25
CL2015001530A1 (es) 2016-03-28
KR102294819B1 (ko) 2021-09-01
MX2020003276A (es) 2020-07-20
HK1212226A1 (en) 2016-06-10
PT3456333T (pt) 2020-06-01
JP6998191B2 (ja) 2022-02-04
EP3646876B1 (en) 2024-02-14
SG10202103341SA (en) 2021-05-28
ME03538B (me) 2020-07-20
RS59363B1 (sr) 2019-11-29
SG11201504383TA (en) 2015-07-30
EP2928477A4 (en) 2016-09-21
PH12015501282B1 (en) 2015-08-24
EP2928477A1 (en) 2015-10-14
AP2015008504A0 (en) 2015-06-30
JP2018035196A (ja) 2018-03-08
NZ708920A (en) 2020-08-28
JP2022179684A (ja) 2022-12-02
IL239266A0 (en) 2015-07-30
TN2015000249A1 (en) 2016-10-03
AU2013356533A1 (en) 2014-06-12
CA2892907C (en) 2023-03-21
CN104936602B (zh) 2020-07-17
MX2022015437A (es) 2023-01-11
EP3456333A1 (en) 2019-03-20
SG10201802926XA (en) 2018-05-30
DK3646876T3 (da) 2024-05-06
ZA202108991B (en) 2023-05-31
PH12015501282A1 (en) 2015-08-24
EA032973B1 (ru) 2019-08-30
KR20210107906A (ko) 2021-09-01
MA38193B1 (fr) 2018-12-31
MA45504A1 (fr) 2020-05-29
MA38193A1 (fr) 2017-12-29
KR20150091130A (ko) 2015-08-07
CY1122169T1 (el) 2020-11-25
CL2017002156A1 (es) 2018-05-04
HUE049858T2 (hu) 2020-11-30
MX2015007169A (es) 2016-03-31
JP6433911B2 (ja) 2018-12-05
HK1210940A1 (en) 2016-05-13
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
EP2928477B1 (en) 2019-07-24
JP2016504307A (ja) 2016-02-12
DK2928477T3 (da) 2019-10-07
EP3646876A1 (en) 2020-05-06
WO2014088785A8 (en) 2015-07-16
AU2013356533B2 (en) 2018-09-27
CN111617252A (zh) 2020-09-04
KR20230028590A (ko) 2023-02-28
PL3456333T3 (pl) 2020-09-21
NZ748134A (en) 2020-10-30
IL239266B (en) 2019-11-28
JP2020041001A (ja) 2020-03-19
SI2928477T1 (sl) 2019-11-29

Similar Documents

Publication Publication Date Title
BR112015013260A2 (pt) uso de inibidores de telomerase para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
NI201500067A (es) Compuestos de pirrolopirimidina como inhibidores de quinasa
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
CL2015002609A1 (es) 2-azabiciclos sustituidos y su uso como moduladores de rectores de orexina.
BR112016009200A8 (pt) uso de um inibidor de btk e um inibidor imune do ponto de verificação
AR089993A1 (es) Macrociclos peptidomimeticos
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
BR112014011925A2 (pt) mutações no receptor notch humano e seu uso
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
EA201391773A1 (ru) Клетки-предшественники мезодермальной линии
BR112015021423A2 (pt) métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
EA201790939A1 (ru) ТРИАЗОЛО[4,5-d]ПИРИМИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНЫХ РЕЦЕПТОРОВ ТИПА 2
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
CL2016000939A1 (es) Compuestos derivados de pirimidina con actividad inhibidora de syk uso en el tratamiento de una condición inmune, enfermedades inflamatorias, trastornos alérgicos, lupus eritomatosos, epoc, bronquitis, rinitis alérgica, asma, entre otras composición farmacéutica que los comprende.
EA201490562A1 (ru) Способы лечения связанной с инсультом сенсорно-двигательной недостаточности с использованием аминопиридинов
EA201490938A1 (ru) Производные спиротиенопиранпиперидина в качестве антагонистов рецептора orl-1 для применения для лечения алкогольной зависимости и злоупотребления алкоголем

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: GERON CORPORATION (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]